当前位置: 首页 > 期刊 > 《中国当代医药》 > 202027
编号:13806754
高敏C反应蛋白/清蛋白比值及血浆和肽素对冠心病合并慢性心力衰竭患者主要不良心血管事件的预测价值(4)
http://www.100md.com 2020年9月25日 《中国当代医药》 202027
     [14]Tentzeris I,Jarai R,Farhan S,et al.Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure[J].Eur J Heart Fail,2011,13(7):726-733.

    [15]Galla OJ,Ylitalo A,Kiviniemi A,et al.Peptide hormones and risk for future cardiovascular events among prediabetics:a 20-year follow-up in the OPERA study[J].Ann Med,2020,52(3-4):85-93.

    [16]于红玖,杨明晖,吕田.慢性心力衰竭患者和肽素、尿酸水平变化及其临床意义[J].大连医科大学学报,2012,34(3):244-247.

    [17]Alehagen U,Dahlstrm U,Rehfeld JF,Goetze JP.Association of Copeptin and N-Terminal proBNP Concentrations With Risk of Cardiovascular Death in Older Patients With Symptoms of Heart Failure[J].JAMA,2011,305(20):2088-2095.

    [18]Yu HJ,Yang MH,Lv T.GW24-e1272 The clinical significance and the expression of copeptin and hemoglobin in patients with chronic heart failure[J].Heart,2013,99(Suppl 3):A223.

    [19]Iwashita N,Nara N,Sato R,et al.Differential Regulation of Plasma Copeptin Levels in Patients with Heart Failure:A Single-Center Prospective Study[J].Tohoku J Exp Med,2016, 239(3):213-221.

    [20]邹莉玲,沈其君,陈启光,等.指標联合的ROC曲线分析[J].中国卫生统计,2003,(5):24-25.

    (收稿日期:2020-06-08), 百拇医药(杜孝芝 王乐)
上一页1 2 3 4